In the coming three to five years, more than half of U.S. CLIA laboratories that perform tumor testing will begin to offer next-generation sequencing (NGS)-based services, according to G2’s recently released report Clinical Next-Gen Tumor Sequencing: Your Key to the Value-Driven Oncology Market. The report, based on qualitative interviews with NGS stakeholders, including hospital and independent laboratories as well as sequencing platform and service vendors, assesses the current state and anticipated evolution of NGS within oncological practice, the current leading clinical area of NGS testing. While the industry marvels at the speed with which the cost of sequencing has plummeted, NGS has for all practical purposes not truly reached the awaited $1,000 per genome threshold. Yet adoption of NGS-based testing is permeating clinical care at a pace unlike any other technology seen in the modern era of laboratory medicine. Clinical NGS testing is currently available for evaluation of somatic mutations in both solid tumors (lung, breast, prostate, or colon) and liquid malignicies (lymphomas, leukemias), although the report finds that the most rapid adoption of NGS testing has been seen in lung cancer care, largely because of the availability of targeted therapies. Only a fraction of the NGS market is for […]